

Special Issue

Treatment of High-Grade Glioma

Message from the Guest Editors

High-grade glioma remains a significant challenge in oncology. Characterized by aggressive growth and poor prognosis, current treatment approaches are diverse yet often insufficient. Surgical resection is designed to remove as much of the tumor as possible, but complete excision is frequently hindered by the tumor's infiltrative nature. Radiation therapy and chemotherapy are important adjuvant treatments, yet they come with various side effects and show limited effectiveness in some patients. Newer treatment modalities, such as targeted therapies and immunotherapies, are emerging, but their optimal use and long-term impacts are still being explored. Additionally, understanding the molecular and genetic characteristics of high-grade glioma is crucial in developing more personalized treatment strategies. For this Special Issue, we welcome original research articles and reviews in the area of high-grade glioma treatment. We aim to explore new treatment strategies, evaluate existing treatments, and discuss the latest research findings in this field.

Guest Editors

Dr. Chiara Valentini

OncoRay-National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden-Rossendorf, 01307 Dresden, Germany

Dr. Silvia Chiesa

Gemelli Advanced Radiotherapy Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy

Deadline for manuscript submissions

31 August 2026



Current Oncology

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 4.9
Indexed in PubMed



mdpi.com/si/260687

Current Oncology
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
currentoncology@mdpi.com

[mdpi.com/journal/
currentoncology](https://mdpi.com/journal/currentoncology)





Current Oncology

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 4.9
Indexed in PubMed



[mdpi.com/journal/
currenocol](https://mdpi.com/journal/currenocol)



About the Journal

Message from the Editor-in-Chief

I am honored and enthusiastic to serve as Editor-in-Chief of *Current Oncology*. Since its establishment in 1994, *Current Oncology* has been playing an important role in the advancement of cancer care by disseminating new knowledge in the cancer care continuum. *Current Oncology* is affiliated with several key cancer societies and provides a global platform to share scientific progress in oncology. We strive for high standards and work together to maintain a rigorous and unbiased peer review process to publish high-quality articles. We have an outstanding editorial team which is committed to the success of *Current Oncology*.

Editor-in-Chief

Prof. Dr. Shahid Ahmed

1. College of Medicine, University of Saskatchewan, Saskatoon, SK S7N5E5, Canada

2. Saskatchewan Cancer Agency, Saskatoon Cancer Center, Saskatoon, SK S7N5H5, Canada

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, and other databases.

Journal Rank:

JCR - Q2 (Oncology)